Banner - NPPA Connect
Logo Image
Opinion|Videos|March 10, 2025

New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Episodes in this series

Video content above is prompted by the following:

Moving on to systemic treatment options, let’s discuss some of the newer systemic treatment options available for pediatric AD, including mechanism of action, efficacy, and safety:

  • JAK inhibitors
  • Nemolizumab

Related Content

Latest CME

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches
Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

View more
Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care
Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

View more